IMMUNISBIO

ImmunisBio is a South Korean biotechnology company specializing in the development of autologous immune cell therapies, with a primary focus on Natural Killer (NK) cells. The company's core technology, MYJ1633, involves a proprietary process for the high-purity culture and potent activation of NK cells derived from a patient's own blood. This platform is being evaluated in clinical trials for various solid tumors, including Phase 2 studies for gastric cancer and Phase 1/2 studies for breast cancer. Beyond oncology, ImmunisBio is exploring the therapeutic potential of NK cells in treating autoimmune diseases and chronic inflammation. The company operates a GMP-certified manufacturing facility to ensure the quality and safety of its cell products. ImmunisBio has also expanded its reach into international markets, establishing partnerships in Vietnam and Japan to provide advanced immunotherapy options.